A Post-Marketing Observational Study of VYXEOS to Assess the Incidence of Infusion-Related Reactions in Adult Patients
Phase of Trial: Phase IV
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Jazz Pharmaceuticals Inc
- 22 Jan 2019 Status changed from not yet recruiting to recruiting.
- 15 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Oct 2018.
- 14 Sep 2018 Planned initiation date changed from 1 Aug 2018 to 1 Sep 2018.